(Tacrolimus 0.5/1/2 mg Capsule)

Trusted Immunomodulator for Grafting
"Ensure Safest Grafting in Organ Transplantation"

Mode of Action:

First-line calcineurin inhibitor

  • It is a calcineurin inhibitor (CNI), inhibits T-cell proliferation by binding to FK 506 binding protein (FKBP).
  • Is an immunosuppressive agent used for prophylaxis of organ rejection post-transplant.
  • Drug of choice for Organ Transplantation
  • Offers better graft survival & has lower incidence of rejection
  • Potent immunosuppressant compared to cyclosporin
  • Offers better safety and efficacy profile

Clinical Benefits for Patients:

  • Effective immunosuppressant & anti-inflammatory.
  • It has more potent immunosuppressant properties compared with cyclosporin, inhibiting cell-mediated and humoral immune responses.
  • Compared with cyclosporin, tacrolimus showed comparable or greater patient/graft survival rates in patients following kidney transplantation & liver allograft recipients (where cost savings associated with reduced hospitalisation costs were evident in one study).
  • It is effective and well tolerated as a second-line therapy in patients with Autoimmune hepatitis

(AIH). Dig Dis Sci. 2021 Aug;66(8):2826-2832.

Rx for:

  • Prophylaxis of organ rejection post-transplant
  • Liver, Heart, Kidney & Lung Transplantation
  • Autoimmune hepatitis (AIH)


  • As directed by the Surgeon & Physician

Excellent Cure -Sure Relief....